1Eleven生物制药公司宣布将在印第安纳州费舍斯开发其下一代肽治疗药物总部-动脉网

1Elevan Biopharmaceuticals, Inc. Announces the Development of Its Next-Generation Peptide Therapeutics Headquarters in Fishers, Indiana

CISION 等信源发布 2025-06-18 00:36



可切换为仅中文







FISHERS, Ind.

印第安纳州费希尔

，

June 17, 2025

2025年6月17日

/PRNewswire/ --

1Elevan Biopharmaceuticals

11家生物制药公司

has officially announced its relocation from

正式宣布了其从...的搬迁

California

加利福尼亚州

到

Fishers, Indiana

印第安纳州费雪斯

, establishing its new headquarters in the Fishers Life Sciences and Innovation Park. The move represents a

，将其新总部设立在菲舍尔生命科学与创新园。此举代表了

$7 million

700万美元

investment in a next-generation facility that will serve as the company's primary operations center.

投资建设下一代设施，该设施将作为公司主要的运营中心。

The new 133,500-square-foot headquarters at 12001 Exit 5 Parkway will house an advanced pharmacy featuring category III, 503A/

位于12001 Exit 5 Parkway的新总部占地133,500平方英尺，将设有一家先进的药房，配备III类503A设施。

503B

compounding capabilities alongside integrated telemedicine services for peptide therapy management and prescription fulfillment. The facility is designed to support the company's phased expansion into peptide manufacturing, innovative drug development, and contract development and manufacturing organization (CDMO) services..

复合能力以及用于肽治疗管理和处方履行的综合远程医疗服务。该设施旨在支持公司分阶段扩展到肽制造、创新药物开发和合同开发及制造组织 (CDMO) 服务。

Fishers

渔民

has emerged as a true epicenter for biopharmaceutical innovation, manufacturing, and distribution,' said

“已经成为生物制药创新、制造和分销的真正中心，”

Darrin Carrico

达林·卡里科

, President and CEO of 1Elevan Bio. 'The city's unique ecosystem of established industry leaders and collaborative biotech companies creates an environment where breakthrough science and unfettered innovation can flourish.'

11Bio的总裁兼首席执行官表示：“该市成熟的行业领袖与协作性生物技术公司构成的独特生态系统，创造了一个能让突破性科学和无拘束创新蓬勃发展的环境。”

1Elevan Bio is redefining the future of medicine through leading-edge scientific research and advanced medication delivery systems. Specializing in FDA-approved and FDA-expanded-access peptides, the company is committed to providing therapies that offer enhanced efficacy, superior safety profiles, and fewer unwanted side effects than traditional pharmaceutical approaches.

1Elevan Bio通过前沿的科学研究和先进的药物递送系统，正在重新定义医学的未来。该公司专注于FDA批准和FDA扩大使用范围的肽类药物，致力于提供比传统制药方法更高效、更安全且副作用更少的治疗方案。

Their focus on precision peptide therapeutics is driving a transformative shift in how diseases are treated—safely and effectively..

他们专注于精准肽类疗法，正在推动疾病治疗方式的安全性和有效性发生革命性的转变。

Fishers

渔民们

has established itself as a hub for innovation in life sciences globally,' said

已经成为全球生命科学创新的中心，' said

Fishers

渔民

Mayor

市长

Scott Fadness

斯科特·法内斯

. 'With today's news from 1Elevan, it shows another example of how our efforts to bring innovative companies and workforce to our community has become a reality. We look forward to seeing the impact 1Elevan will have on its industry in the coming years.'

“今天1Elevan的消息表明，我们为将创新公司和劳动力引入社区所做的努力已成为现实。我们期待看到1Elevan未来几年对其行业产生的影响。”

1Elevan Bio will create 120 specialized positions in

1Elevan Bio将创造120个专业职位在

Indiana

印第安纳州

while maintaining satellite operations in

同时维持卫星运行

California

加利福尼亚州

and

和

Florida

佛罗里达州

to ensure comprehensive national coverage. This strategic distribution enables the company to deliver a complete spectrum of peptide therapeutics and services across key markets.

以确保全国范围的全面覆盖。这一战略性分布使公司能够在关键市场提供全方位的肽类治疗药物和服务。

The move represents a homecoming for several executive team members who are

这一举动代表了几位执行团队成员的回归，他们

Purdue University

普渡大学

alumni. This connection positions 1Elevan Bio to explore strategic partnerships with their alma mater, tapping into cutting-edge research programs and emerging talent in the biopharmaceutical sector.

校友。这一联系使1Elevan Bio能够与其母校探索战略合作，利用生物制药领域的前沿研究项目和新兴人才。

Supporting its aggressive growth strategy, 1Elevan Bio recently appointed

为支持其积极的增长战略，1Elevan Bio最近任命了

Todd Krasinsky, RN

托德·克拉辛斯基，注册护士

, ACLS, TNCC

，高级心脏生命支持（ACLS），创伤护理核心课程（TNCC）

as Chief Commercial Officer. Mr. Krasinsky will spearhead the development of strategic partnerships with peptide industry experts and drive commercial innovation initiatives.

作为首席商务官，Krasinsky先生将领导与肽类行业专家的战略合作伙伴关系的建立，并推动商业创新计划。

With construction actively underway, 1Elevan Bio is positioning itself for rapid market expansion through its next-generation facility and comprehensive service offerings. The company's investment in high-tech infrastructure reflects its commitment to becoming a dominant force in the peptide therapeutics industry..

随着建设积极展开，1Elevan Bio正通过其下一代设施和综合服务定位自己以实现市场的快速扩张。公司对高科技基础设施的投资反映了其致力于成为肽治疗行业的主导力量。

The Fishers City Council formally welcomed 1Elevan Bio during this week's meeting, with the company's arrival highlighted in the City's

费舍尔市议会在本周的会议上正式欢迎了1Elevan Bio公司的到来，该公司的入驻在市里被重点强调。

Economic Development News

经济发展新闻

as a significant addition to the region's growing life sciences cluster.

作为该地区不断发展的生命科学集群的重要补充。

About 1Elevan Biopharmaceuticals

关于11家生物制药公司

Founded in 2022, 1Elevan Bio is dedicated to advancing peptide therapeutics to improve human health and expand patient access to effective treatments. The company delivers FDA-approved and FDA-expanded-access pharmaceutical peptides aimed at treating chronic diseases in adjunctive, first-line, or potentially curative roles.

成立于2022年的1Elevan Bio致力于推进多肽治疗剂的发展，以改善人类健康并扩大患者获得有效治疗的机会。该公司提供FDA批准和FDA扩大使用许可的医药多肽，旨在辅助治疗、一线治疗或潜在治愈慢性疾病。

By leveraging the body's natural pathways, 1Elevan Bio is at the forefront of a shift away from costly, traditional small-molecule drugs with uncertain outcomes—ushering in a new beginning of pharmacological medicine rooted in science, empowerment, and innovation. Learn more at .

通过利用身体的自然途径，1Elevan Bio 正在引领一场远离昂贵、结果不确定的传统小分子药物的转变 —— 开启了以科学、赋权和创新为基础的药理医学新纪元。欲了解更多信息，请访问。

https://1elevan.com

Media Contact:

媒体联系人：

marketing@1elevan.com

, (877) 780-1115

，（877）780-1115

SOURCE 1Elevan Bio

源1：Elevan Bio

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?